During the open-label stabilization phase of a long-term maintenance trial for INVEGA TRINZA ® for the treatment of schizophrenia, enrolled patients treated with RISPERDAL CONSTA ® long-acting injection were switched to INVEGA SUSTENNA ® in place of the next scheduled injection at a dose determined by the conversion guide. 2 It is important to note that the INVEGA SUSTENNA ® conversion dose may not reflect the eventual stabilization dose that was achieved during the remainder of the open-label transition phase.
Risperidone Tablet (T1), Lurasidone (T2), Quetiapine Fumarate Tablet (T2), Clozapine Tablet (T3), Olanzapine Tablet (T3), Asenapine Maleate (T4), Paliperene (T4), Invega Sustenna (T4), Invega Trinza (T4), Risperdal Consta (T4),Ziprasidone HCl胶囊(T4)反胎盘,非典型,D3/D2部分AG-5Risperidone Tablet (T1), Lurasidone (T2), Quetiapine Fumarate Tablet (T2), Clozapine Tablet (T3), Olanzapine Tablet (T3), Asenapine Maleate (T4), Paliperene (T4), Invega Sustenna (T4), Invega Trinza (T4), Risperdal Consta (T4),Ziprasidone HCl胶囊(T4)反胎盘,非典型,D3/D2部分AG-5
治疗类别或品牌名称:可长期注射的非典型抗精神病药适用的药物:Abilify Asimtufii(Aripiprazole),Abilify Maintena(Aripiprazole单饮)(Aripiprazole单水合酸盐),Aristada(AristaDA)(Aripiprazole Lauroxil),Aristada initio lauroxil initio(Aristada Initga)(aripipipipipipiprazole lauroxirine roxirien hase roxirider lauroxiring hafer inseriid roxir inseriid perna in tra fane)棕榈酸酯),Invega sustenna,(棕榈酮棕榈酸酯),Invega trinza(棕榈酮棕榈酸酯),Perseris(Risperidone),Risperdal Consta(Risperidone)(Risperidone),Risvan(Risperidone),Rykindo(Risperidone),Rykindo(Risperidone),uzperidone(risperidone),Risperidone(risperidone) (奥氮平pamoate)
Haloperidol Haldol 1967 Moderate Symptomatology—1–6 mg/d Severe Symptomatology—6–15, up to 100 mg/d Clozapine Clozaril 1989 300–450, up to 900 mg/d Risperidone Risperdal 1993 4–8, up to 16 mg/d Olanzapine Zyprexa 1996 10, up to 20 mg/d Quetiapine Seroquel (also XR) 1997 150–750 mg/d (IR), 400–800 mg/d (XR) Ziprasidone Geodon 2001 40–160, up to 200 mg/d Aripiprazole Abilify 2002 10–15, up to 30 mg/d Paliperidone Invega 2006 3–12 mg/d Asenapine Saphris 2009 10–20 mg/d lurasidone latuda 2010 40–160 mg/d